ZA201008028B - Antibodies to granulocyte-macrophage colony-stimulating factor - Google Patents
Antibodies to granulocyte-macrophage colony-stimulating factorInfo
- Publication number
- ZA201008028B ZA201008028B ZA2010/08028A ZA201008028A ZA201008028B ZA 201008028 B ZA201008028 B ZA 201008028B ZA 2010/08028 A ZA2010/08028 A ZA 2010/08028A ZA 201008028 A ZA201008028 A ZA 201008028A ZA 201008028 B ZA201008028 B ZA 201008028B
- Authority
- ZA
- South Africa
- Prior art keywords
- granulocyte
- antibodies
- stimulating factor
- macrophage colony
- macrophage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4852208P | 2008-04-28 | 2008-04-28 | |
| PCT/US2009/041981 WO2009134805A2 (en) | 2008-04-28 | 2009-04-28 | Antibodies to granulocyte-macrophage colony-stimulating factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201008028B true ZA201008028B (en) | 2012-04-25 |
Family
ID=41255734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/08028A ZA201008028B (en) | 2008-04-28 | 2010-11-09 | Antibodies to granulocyte-macrophage colony-stimulating factor |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8168183B2 (enExample) |
| EP (2) | EP3449941A1 (enExample) |
| JP (1) | JP5688363B2 (enExample) |
| KR (2) | KR101824512B1 (enExample) |
| CN (1) | CN102037016B (enExample) |
| AU (1) | AU2009243184B2 (enExample) |
| BR (1) | BRPI0911902A2 (enExample) |
| CA (1) | CA2722137C (enExample) |
| CO (1) | CO6311004A2 (enExample) |
| DK (1) | DK2280732T3 (enExample) |
| EA (1) | EA201001691A1 (enExample) |
| ES (1) | ES2704835T3 (enExample) |
| IL (1) | IL208980A (enExample) |
| MX (1) | MX2010011761A (enExample) |
| NZ (1) | NZ588850A (enExample) |
| WO (1) | WO2009134805A2 (enExample) |
| ZA (1) | ZA201008028B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2064325B1 (en) | 2006-09-01 | 2011-12-07 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| KR101824512B1 (ko) | 2008-04-28 | 2018-02-02 | 휴머니건, 아이엔씨. | 과립구-대식세포 콜로니 자극 인자에 대한 항체 |
| EP3381471B1 (en) | 2008-12-22 | 2024-03-20 | The University of Melbourne | Pain treatment |
| DK2376121T4 (da) | 2008-12-22 | 2021-08-16 | Univ Melbourne | Slidgigtbehandling |
| US8512950B2 (en) | 2010-07-21 | 2013-08-20 | Saint Louis University | Biolayer interferometry measurement of biological targets |
| BR112013033944A2 (pt) | 2011-07-06 | 2017-12-19 | Morphosys Ag | combinação sinérgica |
| US9400600B2 (en) * | 2011-12-16 | 2016-07-26 | Samsung Electronics Co., Ltd. | Method, apparatus, and graphical user interface for providing visual effects on a touchscreen display |
| WO2013090989A1 (en) | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
| US9833410B2 (en) | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| RU2714919C2 (ru) * | 2013-08-30 | 2020-02-21 | Такеда Гмбх | Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков |
| US11173208B2 (en) | 2014-05-07 | 2021-11-16 | Takeda Gmbh | Liquid formulation comprising GM-CSF neutralizing compound |
| HK1258306A1 (zh) * | 2015-10-29 | 2019-11-08 | F. Hoffmann-La Roche Ag | 具有共同轻链的转基因兔 |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| CN111757744A (zh) * | 2017-10-02 | 2020-10-09 | 人源股份有限公司 | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 |
| EP3849572A4 (en) * | 2018-09-10 | 2022-07-13 | Humanigen, Inc. | METHOD OF TREATMENT OF IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST |
| US12624086B2 (en) | 2018-10-31 | 2026-05-12 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| EP4054602A4 (en) | 2019-11-08 | 2023-12-06 | Mayo Foundation for Medical Education and Research | EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS |
| CN118561999B (zh) * | 2024-06-26 | 2025-03-14 | 武汉爱博泰克生物科技有限公司 | 抗人粒细胞-巨噬细胞集落刺激因子抗体、抗体对及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE444308T1 (de) | 2002-02-13 | 2009-10-15 | Ludwig Inst Cancer Res | Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon |
| CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| WO2004065417A2 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| US7981843B2 (en) | 2004-01-20 | 2011-07-19 | Kalobios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| PL2343380T3 (pl) * | 2004-11-16 | 2020-03-31 | Humanigen, Inc. | Wymiana kasety dla regionu zmiennego immunoglobuliny |
| US7381802B2 (en) * | 2005-04-15 | 2008-06-03 | Universidad Nacional Autónoma De México (UNAM) | Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom |
| MX2007012569A (es) * | 2005-04-18 | 2007-12-06 | Micromet Ag | Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos. |
| ES2918209T3 (es) * | 2005-05-18 | 2022-07-14 | Morphosys Ag | Anticuerpos anti-GM-CSF y usos a partir de los mismos |
| US8211648B2 (en) | 2005-07-22 | 2012-07-03 | Kalobios Pharmaceuticals, Inc. | Secretion of antibodies without signal peptides from bacteria |
| WO2007019620A1 (en) * | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
| KR101395515B1 (ko) * | 2006-02-08 | 2014-05-14 | 모르포테크, 인크. | 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체 |
| US8398972B2 (en) * | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| US20080206241A1 (en) * | 2006-11-21 | 2008-08-28 | Kalobios Pharmaceuticals Inc. | Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| WO2009126659A1 (en) * | 2008-04-07 | 2009-10-15 | Kalobios Pharmaceuticals, Inc. | Neutralization of gm-csf for the treatment of heart failure |
| KR101824512B1 (ko) | 2008-04-28 | 2018-02-02 | 휴머니건, 아이엔씨. | 과립구-대식세포 콜로니 자극 인자에 대한 항체 |
-
2009
- 2009-04-28 KR KR1020107026423A patent/KR101824512B1/ko active Active
- 2009-04-28 US US12/431,661 patent/US8168183B2/en active Active
- 2009-04-28 CN CN200980118423.0A patent/CN102037016B/zh active Active
- 2009-04-28 EP EP18200356.6A patent/EP3449941A1/en not_active Ceased
- 2009-04-28 ES ES09739607T patent/ES2704835T3/es active Active
- 2009-04-28 NZ NZ588850A patent/NZ588850A/xx not_active IP Right Cessation
- 2009-04-28 WO PCT/US2009/041981 patent/WO2009134805A2/en not_active Ceased
- 2009-04-28 BR BRPI0911902A patent/BRPI0911902A2/pt not_active IP Right Cessation
- 2009-04-28 AU AU2009243184A patent/AU2009243184B2/en active Active
- 2009-04-28 JP JP2011507586A patent/JP5688363B2/ja active Active
- 2009-04-28 EP EP09739607.1A patent/EP2280732B1/en active Active
- 2009-04-28 EA EA201001691A patent/EA201001691A1/ru unknown
- 2009-04-28 DK DK09739607.1T patent/DK2280732T3/en active
- 2009-04-28 MX MX2010011761A patent/MX2010011761A/es active IP Right Grant
- 2009-04-28 CA CA2722137A patent/CA2722137C/en active Active
- 2009-04-28 KR KR1020177023943A patent/KR101852915B1/ko active Active
-
2010
- 2010-10-28 IL IL208980A patent/IL208980A/en active IP Right Grant
- 2010-11-09 ZA ZA2010/08028A patent/ZA201008028B/en unknown
- 2010-11-25 CO CO10148019A patent/CO6311004A2/es not_active Application Discontinuation
-
2012
- 2012-04-30 US US13/460,151 patent/US9017674B2/en active Active
-
2015
- 2015-04-02 US US14/677,604 patent/US20150344565A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR101852915B1 (ko) | 2018-04-27 |
| KR20110011638A (ko) | 2011-02-08 |
| NZ588850A (en) | 2012-12-21 |
| CA2722137C (en) | 2019-03-19 |
| IL208980A (en) | 2015-06-30 |
| AU2009243184A1 (en) | 2009-11-05 |
| CA2722137A1 (en) | 2009-11-05 |
| EA201001691A1 (ru) | 2011-10-31 |
| IL208980A0 (en) | 2011-01-31 |
| EP3449941A1 (en) | 2019-03-06 |
| US20120213776A1 (en) | 2012-08-23 |
| EP2280732A2 (en) | 2011-02-09 |
| CN102037016B (zh) | 2015-06-03 |
| JP2011518886A (ja) | 2011-06-30 |
| WO2009134805A2 (en) | 2009-11-05 |
| US20150344565A1 (en) | 2015-12-03 |
| CO6311004A2 (es) | 2011-08-22 |
| US8168183B2 (en) | 2012-05-01 |
| MX2010011761A (es) | 2010-11-30 |
| EP2280732B1 (en) | 2018-10-17 |
| EP2280732A4 (en) | 2012-11-14 |
| JP5688363B2 (ja) | 2015-03-25 |
| WO2009134805A3 (en) | 2010-06-03 |
| KR101824512B1 (ko) | 2018-02-02 |
| AU2009243184B2 (en) | 2015-06-04 |
| US9017674B2 (en) | 2015-04-28 |
| US20090274706A1 (en) | 2009-11-05 |
| BRPI0911902A2 (pt) | 2015-10-13 |
| CN102037016A (zh) | 2011-04-27 |
| DK2280732T3 (en) | 2019-01-28 |
| ES2704835T3 (es) | 2019-03-20 |
| KR20170126458A (ko) | 2017-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL208980A0 (en) | Antibodies to granulocyte-macrophage colony-stimulating factor | |
| ZA201101047B (en) | Antibodies to ccr2 | |
| EP2125890A4 (en) | ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4 | |
| EP2461334B8 (en) | Inductor | |
| PL2150085T3 (pl) | Techniki poprawy współistnienia wielu odbiorników radiowych | |
| GB0815216D0 (en) | Interleukin | |
| SG10201401604VA (en) | Antibodies Specific To Cadherin-17 | |
| GB0903759D0 (en) | Compound | |
| EP2423182A4 (en) | DIACYLETHYLENDIAMINVERBINDUNG | |
| PL2488554T3 (pl) | Przeciwciała przeciw epha3 | |
| GB0922659D0 (en) | Factor H | |
| GB0914767D0 (en) | Compound | |
| ZA201200093B (en) | 3-phenoxymethylpyrrolidine compounds | |
| GB2468871B (en) | Turbocharger | |
| GB0909213D0 (en) | Compound | |
| GB0816577D0 (en) | Growth factor | |
| EP2487178A4 (en) | PYRAZOLOTHIAZOLVERBINDUNG | |
| EP2424402A4 (en) | AVERAGE OF REGULATED CONTRIBUTION | |
| EP2413751A4 (en) | IMPROVEMENTS RELATING TO COVERAGE | |
| GB0914883D0 (en) | Compound | |
| GB201013836D0 (en) | Improvements relating to gutters | |
| GB0806603D0 (en) | Improvements to emissions control | |
| GB0906429D0 (en) | Burn compound | |
| GB0801891D0 (en) | Brekkie to go range | |
| TWM365707U (en) | Improved structure for compound type outer pot |